ReviewJournal of intensive medicine2026
Cast nephropathy in the ICU: Early recognition and extracorporeal strategies to improve outcomes.
Review in Journal of intensive medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cast-induced acute kidney injury (AKI) is a frequent yet under-recognized cause of kidney dysfunction in the intensive care unit. It arises when filtered proteins or pigments - free light chains (FLCs) in multiple myeloma, myoglobin in rhabdomyolysis, bilirubin in severe cholestasis, or hemoglobin in intravascular hemolysis - precipitate within kidney tubules, forming obstructive casts and triggering oxidative and inflammatory injury. Early recognition is essential because traditional markers (creatinine, urine output) rise late. Emerging biomarkers, including neutrophil gelatinase-associated lipocalin (NGAL), cystatin C, and the tissue inhibitor of metalloproteinases-2 · insulin-like growth factor binding protein-7 ([TIMP-2]·[IGFBP7]) panel, detect tubular stress earlier and can guide timely intervention. This narrative review summarizes pathophysiology, diagnostic tools, and extracorporeal strategies tailored to the offending molecule and patient stability. For myeloma cast nephropathy, high cut-off membranes provide robust early FLC clearance but require albumin monitoring; medium cut-off and polymethylmethacrylate membranes offer sustained removal with lower albumin loss. In rhabdomyolysis, continuous kidney replacement therapy with high-flux or newer membranes supports hemodynamic stability and myoglobin clearance; hemoadsorption may be considered in severe cases. In bile cast nephropathy, artificial extracorporeal liver support (e.g., molecular adsorbent recirculating system, fractional plasma separation and adsorption), single-pass albumin dialysis, and hemoadsorption reduce bilirubin and bile acids, while plasma exchange remains reserved mainly for hyperviscosity syndromes. Across etiologies, extracorporeal approaches are most effective when combined with disease-specific treatments, such as chemotherapy for myeloma or targeted therapy for hemolysis. Emerging evidence suggests that integrating artificial intelligence-driven diagnostic tools with these therapeutic strategies may further enhance early recognition and individualized management of renal injury. A patient-centered, pathophysiology-driven strategy can shift extracorporeal therapies from rescue measures to proactive tools that improve kidney recovery and survival. Prospective studies should refine timing, modality selection, and biomarker-based algorithms to optimize outcomes in cast-induced AKI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.